Peptide tyrosine tyrosine (PYY) 1 is member of a 36-amino acid regulatory peptide family that includes neuropeptide Y (NPY) and pancreatic polypeptide (PP). PYY has greater than 70% sequence identity with NPY and shares a common structural motif consisting of two antiparallel helices, an aminoterminal polyproline helix, and a long amphipathic ␣ helix connected by a  turn (1). PYY-secreting cells occur mainly in the distal small intestine and the large intestine, locations where dietary fatty acids can act as potent stimulants of PYY release into the circulation. PYY-induced effects on the gastrointestinal tract can be reproduced by infusions of the peptide at concentrations less than postprandial blood concentrations (2, 3). Specific receptors for NPY/PYY have been characterized in distinct gastrointestinal tissue, such as chief cells (4), and mucosa of the small and large intestine (5). Specific PYY receptors have also been reported in brain tissue (6, 7), spleen (8), vascular smooth muscle (9), and in several neuroendocrine cell lines (10). Such locations make it possible for PYY to act both as an endocrine and a paracrine agent. Many of the reported effects of PYY on the gut, such as the inhibition of intestinal secretion, motility, and gastric acid secretion, occur as interdigestive events coordinated with release of PYY after a meal. We and others have demonstrated that luminal oleic acid induces the release of PYY in the dog (11), rat (12), and in isolated primary cultured PYY cells from the canine mucosa (13). Although it has been proposed that NPY acts centrally to initiate feeding (14), PYY seems to modify digestive processes to ensure efficient utilization of ingested food. PYY acts to slow gastric emptying and intestinal transit, changes that increase the efficiency of nutrient digestion and absorption. In the central nervous system, PYY may act through specific receptors in the dorsal vagal complex to inhibit vagal tone (15). As a result, PYY establishes a negative feedback loop that could act centrally in the brain to inhibit neurally mediated pancreatic exocrine secretion. This negative feedback may serve as part of an "ileal brake" in response to excess dietary triglyceride. For example, triglyceride hydrolysis resulting in FFAs in the distal intestine would induce PYY secretion whenever the rate of triglyceride hydrolysis exceeded the rate of fatty acid absorption. This induction of PYY secretion would then inhibit intestinal motility, causing an increase in FFA absorption and a decrease in luminal FFAs. Therefore PYY, like other gut-regulatory peptides such as cholecystokinin and somatostatin, can act as both a hormone and a neuromodulator.Because PYY secretion can occur in direct response to luminal long-chain FFAs, we chose to examine the possibility that this peptide may act on the expression of an intestinal cytosolic fatty acid-binding protein, the intestinal fatty acid-binding protein (